Comment on draft of hidradenitis suppurativa guidelines
The AAD is seeking member comments on draft clinical practice guidelines on the management of hidradenitis suppurativa (HS). These guidelines provide evidence-based recommendations regarding the efficacy, effectiveness, and adverse effects of HS treatments. The development of these guidelines followed a systematic approach, and recommendations were formed by a guideline work group that included experts in HS management from varied clinical settings, and methodologists. Patient partners were engaged to provide their perspectives during development.
The comment period is open to all AAD members and comments are being accepted through April 27, 2026. Feedback received will be provided to the guideline development work group for review.
If you have questions, please email Sameer Malik at smalik@aad.org.
Draft documents for review
There are two PDFs available for review.
The first is the draft guideline.
The second is the supplement of the guideline.
View the Academy guidelines disclaimer.
